Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | MicrobiomeTrials← Back to trialsNCT04417660
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-12-26Est. Completion: 2026-12-31
Enrollment target: 9 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal CellCarcinoma, Ovarian EpithelialNasopharyngeal CarcinomaCarcinoma, ThymicAnal CancerMesotheliomaEsophagogastric CancerHigh Microsatellite Instability Colorectal CarcinomaSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Neoplasms
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembro…
Boston, United StatesEst. completion Oct 5, 2027
Thymic Epithelial TumorRecurrent ThymomaThymic Cancer
Background:
There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for p…
Bethesda, United StatesEst. completion Dec 31, 2027